
  
    
      
        
        There_EX 's_VBZ a_DT cheap_JJ ,_, common_JJ ,_, and_CC mostly_RB safe_JJ drug_NN ,_, in_IN daily_JJ use_NN for_IN centuries_NNS by_IN hundreds_NNS of_IN
        millions_NNS of_IN people_NNS ,_, that_IN only_RB lately_RB has_VBZ been_VBN investigated_VBN for_IN its_PRP$ therapeutic_JJ potential_NN
        for_IN a_DT long_JJ list_NN of_IN common_JJ ills_NNS ._. The_DT list_NN includes_VBZ Alzheimer_NNP disease_NN ,_, Parkinson_NNP disease_NN ,_,
        depression_NN and_CC anxiety_NN ,_, schizophrenia_NN ,_, attention_NN deficit_NN hyperactivity_NN disorder_NN (_( ADHD_NNP )_) ,_, and_CC
        even_RB pain_NN and_CC obesity_NN ._. Why_WRB has_VBZ interest_NN in_IN this_DT potential_JJ cure-all_JJ been_VBN slow_JJ to_TO develop_VB ?_.
        One_CD reason_NN :_: in_IN its_PRP$ current_JJ forms_VBZ the_DT drug_NN offers_VBZ pharmaceutical_JJ companies_NNS no_DT possibility_NN of_IN
        substantial_JJ profit_NN ._. Another_DT ,_, perhaps_RB more_RBR important_JJ :_: the_DT drug_NN is_VBZ reviled_JJ as_IN the_DT world_NN 's_POS
        most_RBS addictive_JJ ._. The_DT drug_NN ,_, of_IN course_NN ,_, is_VBZ nicotine_NN ._.
        Nicotine_NNP is_VBZ an_DT alkaloid_NN in_IN the_DT tobacco_NN plant_NN 
        Nicotiana_NNP tabacum_NN ,_, which_WDT was_VBD smoked_VBD or_CC chewed_VBD in_IN the_DT Americas_NNPS
        for_IN thousands_NNS of_IN years_NNS before_IN European_JJ invaders_NNS also_RB succumbed_VBD to_TO its_PRP$ pleasures_NNS and_CC shipped_VBD
        it_PRP back_RB to_TO the_DT Old_NNP World_NNP ._. Nicotine_NNP has_VBZ always_RB been_VBN regarded_VBN as_IN medicinal_NN and_CC enjoyable_JJ at_IN
        its_PRP$ usual_JJ low_JJ doses_NNS ._. Native_NNP Americans_NNPS chewed_VBD tobacco_NN to_TO treat_VB intestinal_NN symptoms_NNS ,_, and_CC in_IN
        1560_CD ,_, Jean_NNP Nicot_NNP de_IN Villemain_NNP sent_VBD tobacco_NN seeds_NNS to_TO the_DT French_JJ court_NN ,_, claiming_VBG tobacco_NN had_VBD
        medicinal_NN properties_NNS and_CC describing_VBG it_PRP as_IN a_DT panacea_NN for_IN many_JJ ailments_NNS ._. Higher_JJR doses_NNS are_VBP
        toxic_JJ ,_, even_RB lethal—which_NN is_VBZ why_WRB nicotine_NN is_VBZ used_VBN around_IN the_DT world_NN as_IN an_DT insecticide_NN ._. Yet_RB
        few_JJ of_IN the_DT horrendous_JJ health_NN effects_NNS of_IN smoking_NN are_VBP traceable_JJ to_TO nicotine_NN itself—cigarettes_NNS
        contain_VBP nearly_RB 4_CD ,_, 000_CD other_JJ compounds_NNS that_WDT play_VBP a_DT role_NN ._. Until_IN recently_RB ,_, nicotine_NN research_NN
        has_VBZ been_VBN driven_VBN primarily_RB by_IN nicotine_NN 's_POS unparalleled_JJ power_NN to_TO keep_VB people_NNS smoking_NN ,_, rather_RB
        than_IN its_PRP$ potential_JJ therapeutic_JJ uses_NNS ._.
        Nicotine_NNP locks_NNS on_IN to_TO one_CD group_NN of_IN receptors_NNS that_WDT are_VBP normally_RB targeted_VBN by_IN the_DT
        neurotransmitter_NN acetylcholine_NN ._. Nicotinic_NNP acetylcholine_NN receptors_NNS (_( nAChRs_NNS )_) are_VBP ion_NN channels_NNS
        threaded_JJ through_IN cell_NN membranes_NNS ._. When_WRB activated_VBN ,_, either_CC by_IN acetylcholine_NN or_CC by_IN nicotine_NN ,_,
        they_PRP allow_VBP selected_VBN ions_NNS to_TO flow_VB across_IN the_DT cell_NN membrane_NN ._. In_IN vertebrates_NNS nAChRs_NNS are_VBP all_DT
        over_IN the_DT autonomic_JJ and_CC central_JJ nervous_JJ sytems_NNS and_CC the_DT neuromuscular_NN junction_NN ._. A_DT nAChR_NN is_VBZ
        composed_VBN of_IN five_CD polypeptide_NN subunits_NNS (_( Figure_NN 1_LS )_) ,_, but_CC there_EX are_VBP many_JJ nAChR_NN subtypes_NNS made_VBN of_IN
        different_JJ subunit_NN combinations_NNS ,_, a_DT diversity_NN that_WDT helps_VBZ explain_VB why_WRB nicotine_NN can_MD have_VB so_RB
        many_JJ different_JJ physiological_JJ and_CC cognitive_JJ effects_NNS ._.
        It_PRP is_VBZ now_RB conventional_JJ wisdom_NN that_DT acetylcholine_NN and_CC nicotine_NN act_NN at_IN these_DT receptors_NNS to_TO
        alter_VB electrochemical_JJ properties_NNS at_IN a_DT variety_NN of_IN synapses_NNS ,_, which_WDT can_MD in_IN turn_VB affect_VB the_DT
        release_NN of_IN several_JJ other_JJ neurotransmitters_NNS ._. This_DT wisdom_NN exists_VBZ thanks_NNS in_IN part_NN to_TO work_VB by_IN
        Lorna_NNP Role_NNP and_CC her_PRP$ colleagues_NNS at_IN Columbia_NNP University_NNP in_IN New_NNP York_NNP City_NNP ._. “ In_IN 1995_CD ,_, we_PRP turned_VBD
        people_NNS 's_POS attention_NN to_TO how_WRB nicotine_NN works_VBZ as_IN a_DT modulator_NN ,_, tuning_VBG synapses_NNS and_CC increasing_VBG the_DT
        gain_NN on_IN transmitter_NN release_NN ,_,” Role_NNP recalls_VBZ ._. Although_IN all_DT nAChRs_NNS are_VBP activated_VBN by_IN nicotine_NN ,_,
        other_JJ drugs_NNS could_MD be_VB found_VBN or_CC designed_VBN that_WDT affect_VBP only_RB a_DT subset_NN of_IN these_DT receptor_NN types_NNS ._.
        “ If_IN you_PRP can_MD dissect_NN out_RP the_DT important_JJ players_NNS with_IN respect_NN to_TO which_WDT nicotine_NN receptors_NNS are_VBP
        tuning_VBG [_NN a_DT ]_NN particular_RB set_NN of_IN synapses_NNS ,_, then_RB that_WDT provides_VBZ another_DT way_NN to_TO potentially_RB target_VB
        the_DT therapeutics_NNS ._.”
      
      
        Nicotine_NNP and_CC the_DT Brain_NNP
        People_NNS with_IN depressive-spectrum_JJ disorders_NNS ,_, schizophrenia_NN ,_, and_CC adult_NN ADHD_NNP tend_VBP to_TO smoke_VB
        heavily_RB ,_, which_WDT suggested_VBD to_TO researchers_NNS that_WDT nicotine_NN may_MD soothe_VB their_PRP$ symptoms_NNS ._. Common_NNP to_TO
        all_DT these_DT disorders_NNS is_VBZ a_DT failure_NN of_IN attention_NN ,_, an_DT inability_NN to_TO concentrate_VB on_IN particular_JJ
        stimuli_NNS and_CC screen_NN out_RP the_DT rest_NN ._. Nicotine_NNP helps_VBZ ._. Researchers_NNS at_IN the_DT National_NNP Institute_NNP on_IN
        Drug_NNP Abuse_NNP have_VBP shown_VBN via_IN functional_JJ magnetic_JJ resonance_NN imaging_NN that_IN nicotine_NN activates_NNS
        specific_JJ brain_NN areas_NNS during_IN tasks_NNS that_WDT demand_NN attention_NN (_( Box_NNP 1_LS )_) ._. This_DT may_MD be_VB because_IN of_IN its_PRP$
        effects_NNS ,_, shared_VBN with_IN many_JJ other_JJ addictive_JJ drugs_NNS ,_, on_IN the_DT release_NN of_IN the_DT neurotransmitter_NN
        dopamine_NN ._. “ Schizophrenia_NNP is_VBZ a_DT disorder_NN largely_RB of_IN the_DT dopamine_NN system_NN ,_,” says_VBZ John_NNP Dani_NNP of_IN
        the_DT Baylor_NNP College_NNP of_IN Medicine_NNP in_IN Houston_NNP ,_, Texas_NNP ._. Dopamine_NNP signals_NNS in_IN the_DT brain_NN occur_VB in_IN
        two_CD modes—a_NN kind_NN of_IN background_NN trickle_NN ,_, punctuated_JJ by_IN brief_JJ bursts_NNS ._. “ It_PRP 's_VBZ thought_VBD that_IN
        schizophrenics_NNS have_VBP a_DT hard_JJ time_NN separating_VBG that_DT background_NN information_NN from_IN important_JJ
        bursts_NNS ._. We_PRP 've_VBP shown_VBN that_DT nicotine_NN helps_VBZ to_TO normalize_VB that_IN signaling_VBG by_IN depressing_VBG the_DT
        background_NN but_CC letting_VBG the_DT bursts_NNS through_IN well_RB ,_,” he_PRP says_VBZ ._. “ I_PRP 'll_MD be_VB surprised_VBN if_IN there_EX 's_VBZ not_RB
        a_DT co-therapy_JJ [_NN to_TO help_VB schizophrenics_NNS ]_NN that_WDT takes_VBZ advantage_NN of_IN nicotine_NN systems_NNS in_IN less_JJR than_IN
        a_DT decade_NN ._.”
        Nicotine_NNP may_MD be_VB the_DT link_NN between_IN two_CD genes_NNS that_WDT appear_VBP to_TO figure_VB in_IN schizophrenia_NN ._.
        Sherry_NNP Leonard_NNP and_CC Robert_NNP Freedman_NNP of_IN the_DT University_NNP of_IN Colorado_NNP in_IN Denver_NNP ,_, Colorado_NNP ,_, have_VBP
        shown_VBN that_DT expression_NN of_IN the_DT gene_NN for_IN the_DT alpha_NN 7_CD neuronal_NN nicotinic_JJ receptor_NN is_VBZ reduced_VBN in_IN
        schizophrenics_NNS ,_, and_CC have_VBP argued_VBN that_DT alpha_NN 7_CD abnormalities_NNS lead_VBP to_TO attention_NN problems_NNS ._.
        Researchers_NNS in_IN Iceland_NNP and_CC elsewhere_RB have_VBP shown_VBN that_IN a_DT different_JJ gene_NN ,_, for_IN the_DT growth_NN
        factor_NN neuregulin_NN ,_, also_RB appears_VBZ to_TO figure_VB in_IN the_DT disease_NN ._. Neuregulin_NNP ,_, Role_NNP and_CC her_PRP$
        colleagues_NNS have_VBP shown_VBN ,_, governs_NNS the_DT expression_NN of_IN nAChRs_NNS in_IN neurons_NNS and_CC helps_VBZ to_TO stabilize_VB
        the_DT synapses_NNS where_WRB they_PRP are_VBP found_VBN ._. The_DT researchers_NNS are_VBP currently_RB studying_VBG interactions_NNS
        between_IN neuregulin_NN and_CC alpha_NN 7_CD ,_, which_WDT Role_NNP thinks_VBZ will_MD prove_VB important_JJ ._.
        Smokers_NNS also_RB have_VBP lower_JJR rates_NNS of_IN neurodegenerative_JJ disorders_NNS ,_, and_CC nicotine_NN improves_VBZ
        cognitive_JJ and_CC motor_NN functioning_VBG in_IN people_NNS with_IN Alzheimer_NNP disease_NN and_CC Parkinson_NNP disease_NN ._. The_DT
        prevailing_VBG hypothesis_NNS is_VBZ that_IN nicotine_NN increases_NNS release_NN of_IN neurotransmitters_NNS depleted_VBN in_IN
        those_DT diseases_NNS ._. Dani_NNP and_CC his_PRP$ colleagues_NNS have_VBP recently_RB shown_VBN that_DT acetylcholinesterase_NN
        inhibitors—which_NN block_VBP the_DT degradation_NN of_IN acetylcholine_NN and_CC hence_RB prolong_VB its_PRP$ action—used_JJ
        to_TO treat_VB Alzheimer_NNP disease_NN also_RB stimulate_VB dopamine_NN release_NN ._. They_PRP suspect_VBP that_IN
        malfunctioning_VBG of_IN the_DT dopamine_NN system_NN may_MD be_VB affecting_VBG noncognitive_JJ aspects_NNS of_IN dementia_NN
        such_JJ as_IN depressed_VBN mood_NN ,_, and_CC that_IN this_DT might_MD be_VB alleviated_JJ by_IN nicotine_NN ._.
        Paul_NNP Newhouse_NNP and_CC his_PRP$ colleagues_NNS at_IN the_DT University_NNP of_IN Vermont_NNP in_IN Burlington_NNP ,_, Vermont_NNP ,_,
        are_VBP studying_VBG nicotine_NN drugs_NNS as_IN potential_JJ therapeutic_JJ agents_NNS for_IN cognitive_JJ dysfunction_NN ._.
        Newhouse_NNP ,_, a_DT long-time_JJ nicotine_NN researcher_NN ,_, is_VBZ heading_VBG the_DT first_JJ study_NN ever_RB to_TO examine_VB the_DT
        efficacy_NN and_CC safety_NN of_IN nicotine_NN patches_NNS for_IN treating_VBG mild_JJ cognitive_JJ impairment_NN ,_, thought_VBD to_TO
        be_VB a_DT precursor_NN of_IN Alzheimer_NNP disease_NN ._. The_DT researchers_NNS hope_VBP to_TO see_VB a_DT positive_JJ effect_NN on_IN
        attention_NN and_CC learning_VBG ._. Newhouse_NNP also_RB heads_VBZ two_CD studies_NNS of_IN nicotinic_JJ stimulation_NN in_IN ADHD_NNP ,_,
        using_VBG the_DT patch_NN ,_, nicotine_NN blockers_NNS ,_, and_CC some_DT novel_NN drugs_NNS that_WDT activate_VBP nicotine_NN
        receptors_NNS ._.
      
      
        Nicotine_NNP and_CC Pain_NNP
        Nicotine_NNP 's_POS salutary_JJ effects_NNS in_IN patients_NNS with_IN neurodegenerative_JJ and_CC mental_JJ disorders_NNS have_VBP
        been_VBN studied_VBN a_DT lot_NN and_CC are_VBP fairly_RB well_RB known_VBN ._. Two_CD much_RB newer_JJR topics_NNS of_IN academic_JJ research_NN
        are_VBP nicotine_NN 's_POS potential_JJ for_IN pain_NN relief_NN and_CC for_IN treating_VBG obesity_NN ._. Nicotine_NNP itself_PRP has_VBZ
        provided_VBN modest_JJ pain_NN relief_NN in_IN animal_NN studies_NNS ._. Although_IN the_DT analgesic_JJ effect_NN of_IN drugs_NNS that_WDT
        mimic_VBP acetylcholine_NN were_VBD originally_RB attributed_VBN to_TO a_DT different_JJ class_NN of_IN receptors_NNS ,_, it_PRP is_VBZ now_RB
        clear_JJ that_IN nAChRs_NNS play_VBP an_DT important_JJ role_NN in_IN the_DT control_NN of_IN pain_NN ._. For_IN instance_NN ,_, epibatidine_NN ,_,
        a_DT drug_NN that_WDT is_VBZ extracted_VBN from_IN the_DT skin_NN of_IN an_DT Ecuadorian_NNP frog_NN and_CC that_IN acts_NNS at_IN nAChRs_NNS ,_, has_VBZ
        been_VBN shown_VBN to_TO be_VB 200_CD times_NNS more_RBR potent_JJ than_IN morphine_NN at_IN blocking_VBG pain_NN in_IN animals_NNS ._. Current_JJ
        animal_NN research_NN is_VBZ aimed_VBN at_IN discovering_VBG just_RB where_WRB ,_, how_WRB ,_, and_CC which_WDT classes_NNS of_IN nAChRs_NNS work_VBP
        against_IN pain_NN ,_, with_IN the_DT aim_NN of_IN developing_VBG more_RBR selective_JJ drugs_NNS ._.
        Meanwhile_RB ,_, nicotine_NN is_VBZ also_RB being_VBG investigated_VBN as_IN an_DT analgesic_JJ in_IN humans_NNS ._. For_IN example_NN ,_,
        Pamela_NNP Flood_NNP ,_, an_DT anesthesiologist_NN at_IN Columbia_NNP ,_, is_VBZ investigating_VBG nicotine_NN 's_POS future_NN as_IN a_DT
        postoperative_JJ analgesic_JJ ._. She_PRP recently_RB completed_VBD a_DT pilot_NN study_NN of_IN 20_CD women_NNS undergoing_VBG
        gynecological_JJ surgery_NN ._. All_DT the_DT women_NNS had_VBD access_NN to_TO unlimited_JJ morphine_NN and_CC also_RB got_VBD either_CC a_DT
        single_JJ 3_CD -_: mg_NN dose_NN of_IN nicotine_NN nasal_NN spray_NN or_CC a_DT placebo_NN ._. The_DT placebo_NN group_NN had_VBD peak_NN pain_NN
        scores_NNS of_IN eight_CD out_IN of_IN a_DT possible_JJ ten_CD in_IN the_DT first_JJ hour_NN after_IN surgery_NN ._. Women_NNP who_WP got_VBD
        nicotine_NN averaged_VBD a_DT pain_NN score_NN of_IN five_CD ._. Despite_IN the_DT small_JJ sample_NN size_NN ,_, Flood_NNP says_VBZ ,_, the_DT
        results_NNS were_VBD highly_RB significant_JJ ._. “ As_RB far_RB as_IN I_PRP know_VBP this_DT is_VBZ the_DT first_JJ clinical_JJ study_NN to_TO use_VB
        nicotine_NN for_IN analgesia_NN ,_, and_CC it_PRP was_VBD much_RB more_RBR successful_JJ than_IN I_PRP ever_RB would_MD have_VB
        imagined_VBN ._.”
        “ The_DT nice_JJ thing_NN about_IN nicotine_NN and_CC drugs_NNS like_IN nicotine_NN is_VBZ that_IN they_PRP have_VBP opposite_JJ side_NN
        effects_NNS to_TO anesthetics_NNS ._. Instead_RB of_IN being_VBG respiratory_JJ depressants_NNS ,_, they_PRP are_VBP respiratory_JJ
        stimulants_NNS ._. Instead_RB of_IN being_VBG sedating_VBG ,_, they_PRP increase_VBP alertness_NNS ._. So_RB theoretically_RB this_DT class_NN
        of_IN drugs_NNS is_VBZ actually_RB the_DT perfect_JJ thing_NN to_TO add_VB to_TO an_DT opioid_NN regimen_NN ._. The_DT fact_NN that_IN they_PRP 're_VBP
        synergistic_JJ was_VBD a_DT fortuitous_JJ thing_NN that_IN we_PRP had_VBD never_RB looked_VBN at_IN ,_, and_CC neither_DT had_VBN anybody_NN
        else_RB ._.”
      
      
        Nicotine_NNP and_CC Weight_NNP Gain_NNP
        Nicotine_NNP may_MD be_VB the_DT most_RBS effective_JJ drug_NN around_IN for_IN weight_NN control_NN ._. As_IN ex-smokers_JJ know_VB ,_,
        to_TO their_PRP$ rue_NN ,_, one_CD of_IN the_DT worst_JJS things_NNS about_IN quitting_VBG cigarettes_NNS is_VBZ putting_VBG on_IN pounds—as_NNS
        much_JJ as_IN 10_CD %_NN of_IN body_NN weight_NN ._. “ Something_NN about_IN being_VBG addicted_VBN to_TO nicotine_NN and_CC then_RB going_VBG off_RP
        it_PRP causes_VBZ massive_JJ increase_NN in_IN weight_NN ,_,” Role_NNP points_NNS out_RP ._.
        Young-_NNP Hwan_NNP Jo_NNP in_IN Role_NNP 's_POS lab_NN is_VBZ looking_VBG at_IN a_DT particular_JJ brain_NN circuit_NN involved_VBN in_IN
        motivational_NN behavior_NN ,_, especially_RB feeding_NN behavior_NN ._. It_PRP is_VBZ lodged_VBN primarily_RB in_IN the_DT lateral_NN
        hypothalamus_JJ but_CC has_VBZ projections_NNS all_DT over_IN the_DT cortex_NN ,_, especially_RB the_DT nucleus_NN accumbens_NNS ,_,
        which_WDT is_VBZ the_DT center_NN of_IN reinforcement_NN ._. “ This_DT is_VBZ where_WRB information_NN that_WDT has_VBZ come_VBN in_IN to_TO the_DT
        thalamus_JJ and_CC the_DT hypothalamus_JJ is_VBZ relayed_VBD to_TO cortical_JJ areas_NNS with_IN some_DT sense_NN of_IN salience_NN or_CC
        remembrance_NN ._. It_PRP presumably_RB is_VBZ involved_VBN in_IN changing_VBG perception_NN and_CC motivation_NN for_IN eating_VBG ._.
        It_PRP 's_VBZ not_RB ,_, ‘ I_PRP have_VBP to_TO eat_VB this_DT ,_,’ it_PRP 's_VBZ ,_, ‘ I_PRP want_VBP to_TO eat_VB this_DT ,_,’” says_VBZ Role_NNP ._.
        Jo_NNP has_VBZ been_VBN comparing_VBG the_DT synaptic_JJ effects_NNS of_IN nicotine_NN ,_, which_WDT reduces_VBZ appetite_NN ,_, to_TO those_DT
        of_IN cannabinoids_NNS ,_, which_WDT stimulate_VB it_PRP ._. “ Control_NNP of_IN these_DT projection_NN neurons_NNS seems_VBZ to_TO be_VB
        oppositely_RB regulated_VBN by_IN these_DT two_CD ,_,” Role_NNP notes_NNS ._. “ It_PRP does_VBZ n't_RB necessarily_RB mean_VB we_PRP 've_VBP found_VBN
        the_DT root_NN of_IN the_DT munchies_NNS ,_, but_CC it_PRP at_IN least_JJS points_NNS to_TO pathways_NNS that_IN these_DT things_NNS have_VBP in_IN
        common_NN ._.” Jo_NNP is_VBZ also_RB examining_VBG how_WRB nicotine_NN and_CC cannabinoids_NNS modulate_VBP these_DT pathways_NNS in_IN
        genetically_RB obese_NN mice_NNS ,_, and_CC also_RB their_PRP$ interactions_NNS with_IN leptins_NNS ._. Role_NNP says_VBZ tuning_VBG these_DT
        pathways_NNS up_RB or_CC down_RB might_MD be_VB a_DT reasonable_JJ aim_NN ._. “ If_IN that_DT could_MD be_VB done_VBN in_IN a_DT selective_JJ
        fashion_NN ,_, maybe_RB that_WDT could_MD be_VB introduced_VBN in_IN appetite_NN control_NN ._. Certainly_RB I_PRP see_VBP …_NN antagonism_NN of_IN
        some_DT of_IN these_DT pathways_NNS that_WDT nicotine_NN activates_NNS or_CC the_DT complementary_JJ activation_NN of_IN the_DT
        cannabinoid_NN pathways_NNS as_RB very_RB important_JJ targets_NNS for_IN therapeutics_NNS with_IN respect_NN to_TO the_DT
        anorexia_NN that_WDT 's_VBZ associated_VBN with_IN chemotherapy_NN ._.”
        Ming_NNP Li_NNP and_CC his_PRP$ colleagues_NNS at_IN the_DT University_NNP of_IN Texas_NNP in_IN San_NNP Antonio_NNP ,_, Texas_NNP ,_, are_VBP
        studying_VBG nicotine_NN 's_POS effects_NNS on_IN weight_NN and_CC on_IN expression_NN of_IN genes_NNS that_WDT nicotine_NN upregulates_NNS
        orexin_NN and_CC neuropeptide_NN Y_NNP and_CC ,_, more_RBR recently_RB ,_, that_IN it_PRP also_RB regulates_VBZ leptin_NN signaling_VBG ._. All_DT
        three_CD molecules_NNS regulate_VB feeding_NN behavior_NN controlled_VBN by_IN the_DT hypothalamus_JJ ._. In_IN the_DT weight_NN
        study_NN ,_, nicotine-treated_JJ rats_NNS not_RB only_RB lost_VBD weight_NN ,_, they_PRP lost_VBD about_IN 20_CD %_NN of_IN their_PRP$ body_NN fat_JJ
        compared_VBN to_TO saline-treated_JJ controls_NNS ._. The_DT researchers_NNS suggest_VBP that_IN ,_, among_IN its_PRP$ other_JJ effects_NNS ,_,
        nicotine_NN alters_NNS fat_JJ storage_NN ._.
        The_DT University_NNP of_IN Texas_NNP researchers_NNS have_VBP scoured_JJ the_DT literature_NN for_IN genes_NNS related_VBN to_TO
        nicotine_NN ,_, and_CC they_PRP are_VBP developing_VBG microarrays_NNS to_TO study_VB the_DT expression_NN of_IN these_DT genes_NNS
        (_( Figure_NN 3_LS )_) ._. While_IN nicotine_NN seems_VBZ to_TO affect_VB all_DT the_DT molecules_NNS known_VBN to_TO influence_VB weight_NN ,_, Li_NNP
        says_VBZ it_PRP 's_VBZ clear_VB the_DT story_NN is_VBZ even_RB more_RBR complex_JJ ._. “ That_DT 's_VBZ the_DT reason_NN we_PRP keep_VBP looking_VBG at_IN
        different_JJ molecules_NNS ,_, to_TO find_VB key_JJ targets_NNS involved_VBN in_IN this_DT regulation_NN ._.” The_DT ultimate_JJ hope_NN is_VBZ
        to_TO develop_VB new_JJ drug_NN applications_NNS ._.
        Dani_NNP predicts_VBZ that_DT weight_NN control_NN is_VBZ likely_JJ to_TO be_VB one_CD of_IN the_DT earliest_JJS nicotine-based_JJ
        therapies_NNS ._. “ There_EX 's_VBZ a_DT very_RB good_JJ chance_NN that_IN the_DT first_JJ drug_NN is_VBZ unlikely_JJ to_TO be_VB …_NN nicotine_NN
        itself_PRP ,_, but_CC will_MD take_VB advantage_NN of_IN nicotinic_JJ receptors_NNS in_IN the_DT therapy_NN ,_,” he_PRP says_VBZ ._. “ I_PRP know_VBP
        there_EX are_VBP drugs_NNS now_RB being_VBG tested_VBN by_IN drug_NN companies_NNS just_RB for_IN that_DT purpose_NN ._.”
      
      
        Nicotine_NNP 's_POS Future_NNP
        Developing_VBG new_JJ drugs_NNS that_WDT selectively_RB target_NN specific_JJ subtypes_NNS of_IN nicotine_NN receptors_NNS is_VBZ
        an_DT expensive_JJ ,_, albeit_IN potentially_RB lucrative_JJ ,_, proposition_NN ._. And_CC therein_RB lies_VBZ a_DT question_NN ._. Will_MD
        nicotine-based_JJ therapy_NN consist_VB mostly_RB of_IN costly_JJ new_JJ drugs_NNS from_IN the_DT pharmaceutical_JJ industry_NN ?_.
        Or_CC can_MD less_RBR expensive_JJ nicotine_NN products_NNS like_IN the_DT patch_NN ,_, chewing_VBG gum_NN ,_, and_CC nasal_NN spray—which_NN
        are_VBP generally_RB intended_VBN for_IN smoking_NN cessation_NN but_CC widely_RB available_JJ ,_, usually_RB without_IN
        prescription—find_NN their_PRP$ way_NN into_IN the_DT world_NN 's_POS medicine_NN cabinets_NNS ?_.
        “ It_PRP 's_VBZ a_DT little_RB early_JJ to_TO call_VB whether_IN nicotine_NN will_MD be_VB used_VBN itself_PRP as_IN a_DT therapeutic_JJ agent_NN
        or_CC whether_IN these_DT more_RBR specific_JJ drugs_NNS that_WDT are_VBP being_VBG produced_VBN or_CC maybe_RB even_RB used_VBN in_IN
        combination_NN with_IN other_JJ drugs_NNS may_MD be_VB the_DT most_RBS important_JJ way_NN to_TO go_VB ,_,” says_VBZ Dani_NNP ._. But_CC he_PRP
        does_VBZ n't_RB see_VB the_DT medicinal_NN use_NN of_IN plain_JJ nicotine_NN as_RB very_RB likely_JJ ._. Dani_NNP points_NNS out_RP that_IN the_DT
        body_NN 's_POS own_JJ agent_NN ,_, acetylcholine_NN ,_, acts_NNS over_IN milliseconds_NNS to_TO activate_VBP nicotinic_JJ receptors_NNS ,_,
        whereas_IN nicotine_NN itself_PRP stimulates_NNS these_DT receptors_NNS for_IN hours_NNS ._. That_DT lengthy_JJ action_NN means_VBZ
        that_IN ,_, although_IN nicotine_NN activates_NNS the_DT receptors_NNS ,_, it_PRP then_RB often_RB turns_VBZ particular_JJ receptor_NN
        subtypes_NNS off_RP again_RB ,_, a_DT process_NN called_VBD desensitization_NN ._. “ It_PRP 's_VBZ hard_JJ to_TO predict_VB inside_IN of_IN a_DT
        body_NN what_WP you_PRP 're_VBP getting_VBG ._. Am_NNP I_PRP getting_VBG an_DT activation_NN or_CC am_VBP I_PRP turning_VBG the_DT receptors_NNS
        off_RP ?_.”
        Yet_RB much_JJ of_IN the_DT work_NN to_TO date_NN showing_VBG nicotine_NN 's_POS effectiveness_NN on_IN a_DT huge_JJ range_NN of_IN
        disorders_NNS has_VBZ involved_VBN products_NNS available_JJ at_IN any_DT drugstore_NN and_CC intended_VBN to_TO help_VB people_NNS quit_VBD
        smoking_VBG ._. Newhouse_NNP is_VBZ using_VBG patches_NNS for_IN mild_JJ cognitive_JJ impairment_NN ._. Flood_NNP has_VBZ demonstrated_VBN
        pain_NN relief_NN with_IN nasal_NN spray_NN and_CC will_MD use_VB patches_NNS in_IN her_PRP$ next_JJ study_NN ._. And_CC Role_NNP feels_VBZ that_DT
        gum_NN has_VBZ n't_RB been_VBN adequately_RB explored_JJ for_IN its_PRP$ therapeutic_JJ potential_NN ._. Nicotine_NNP gum_NN ,_, she_PRP notes_VBZ ,_,
        is_VBZ a_DT better_JJR imitator_NN of_IN smoking_NN than_IN the_DT patch_NN because_IN it_PRP delivers_VBZ brief_JJ hits_NNS rather_RB than_IN a_DT
        steady_JJ supply_NN ._. She_PRP 's_VBZ also_RB uncertain_JJ whether_IN natural_JJ nicotine_NN has_VBZ been_VBN studied_VBN enough_RB ._. But_CC
        Role_NNP also_RB points_VBZ out_RP that_IN nicotine_NN has_VBZ its_PRP$ serious_JJ problems—addictive_JJ potential_JJ ,_,
        cardiovascular_JJ damage_NN ,_, and_CC (_( especially_RB when_WRB delivered_VBN through_IN the_DT mucosa_NN )_) cancer_NN ._.
        Dani_NNP says_VBZ ,_, “ People_NNS are_VBP probably_RB going_VBG to_TO have_VB to_TO find_VB creative_JJ ways_NNS to_TO understand_VB which_WDT
        subtypes_NNS of_IN nicotinic_JJ receptors_NNS they_PRP 're_VBP turning_VBG on_IN and_CC which_WDT ones_NNS they_PRP 're_VBP desensitizing_VBG ._.
        Maybe_RB drug_NN delivery_NN methods_NNS will_MD matter_VB ._. Maybe_RB subtype_NN specificity_NN will_MD matter_VB ._. It_PRP 's_VBZ less_JJR
        than_IN a_DT decade_NN that_IN we_PRP 've_VBP known_VBN how_WRB important_JJ nicotinic_JJ receptors_NNS are_VBP ._. Now_RB we_PRP have_VBP to_TO move_VB
        forward_RB from_IN there_RB ._.”
        “ We_PRP 've_VBP made_VBN an_DT enormous_JJ amount_NN of_IN progress_NN on_IN understanding_VBG the_DT biology_NN of_IN these_DT
        receptor_NN systems_NNS and_CC how_WRB to_TO target_VB them_PRP ._. What_WP has_VBZ been_VBN trickier_JJR has_VBZ been_VBN to_TO develop_VB an_DT
        appropriate_JJ pharmacology_NN that_WDT allows_VBZ one_CD to_TO selectively_RB target_VB agents_NNS for_IN particular_JJ
        therapeutic_JJ purposes_NNS with_IN an_DT adequate_JJ safety_NN index_NN ,_,” Newhouse_NNP says_VBZ ._. “ But_CC some_DT of_IN the_DT drugs_NNS
        that_WDT are_VBP coming_VBG on_IN in_IN human_JJ trials_NNS now_RB are_VBP very_RB promising_JJ ._. So_IN I_PRP 'm_VBP cautiously_RB optimistic_JJ
        that_IN we_PRP 're_VBP on_IN the_DT road_NN to_TO developing_VBG some_DT useful_JJ nicotinic_JJ therapies_NNS ._.”
      
    
  
